Trichloroethylene (TCE) is an industrial solvent that has been used extensively in industrial operations involving metal cleaning and degreasing. Its metabolism through a cytochrome P450 (CYP) pathway involving the enzyme CYP2E1 results in numerous metabolites, including chloral, chloral hydrate, dichloroacetic acid, trichloracetic acid, trichloroethanol, and trichloroethanol glucuronide ([@b40-ehp-117-696]). Many studies of immune-related effects of TCE have been conducted in the past decade, with much of this work focusing on autoimmune disease. We reviewed this recent research to determine the strength and consistency of data from experimental and epidemiologic studies, and the concordance between human and animal data, pertaining to these effects.

Materials and Methods
=====================

We searched PubMed ([@b48-ehp-117-696]) for studies related to TCE and immune effects, using forms of "immune," "autoimmune," "immunosuppression," "cytokines," "lupus," "scleroderma," "rheumatoid arthritis," "vasculitis," and "liver" as search terms. We also reviewed references within relevant reports, including the National Academy of Sciences 2006 report on TCE ([@b49-ehp-117-696]). We did not include studies of *in utero* or developmental exposures ([@b4-ehp-117-696]; [@b4-ehp-117-696]; [@b53-ehp-117-696], [@b54-ehp-117-696]) in this review.

We abstracted data pertaining to immunosuppression, hypersensitivity, and autoimmune-related effects, including clinically expressed or clinically diagnosed disease, cytokine expression or levels, T-cell activation, and serology \[antinuclear antibodies (ANA) and specific autoantibodies\]. We present, in tabular form, end points that all, or almost all, of the identified reports examined and include information on both "positive" and "negative" effects found in the studies.

We identified three case--control studies of scleroderma (systemic sclerosis) risk that included a specific assessment of occupational exposure to TCE in addition to more general assessments of "solvent" or "organic solvent" exposure ([@b15-ehp-117-696]; [@b19-ehp-117-696]; [@b50-ehp-117-696]). We created graphical displays of the estimated measures of association from these studies using Comprehensive Meta Analysis, version 2.2.046 (Biostat, Inc., Englewood, NJ). We conducted a meta-analysis of these studies using a random-effects model to include the possibility of nonrandom error between studies ([@b14-ehp-117-696]). Studies were too sparse to do sensitivity analyses or explore sources of heterogeneity or potential publication bias.

Results
=======

Immunosuppression Studies
-------------------------

Several animal studies have examined immunosuppression and host resistance in relation to TCE exposures by various routes and concentrations of exposure. CD1 mice exhibited an increase in susceptibility to infectious agents (e.g., *Streptococcus zooepidimicus*, *Klebsiella pneumoniae*) with short-term (3-hr) inhalation TCE exposures ranging from 2.6 to 48 ppm ([@b1-ehp-117-696]). Another study in female CD1 mice provided evidence of decreased humoral immunity with oral exposure (via drinking water) to TCE at concentrations of 0.1, 1, 2.5, or 5 mg/mL for 3--6 months ([@b56-ehp-117-696]). [@b32-ehp-117-696] found similar results in a study of male and female CD1 mice exposed to a TCE metabolite, chloral hydrate, at concentrations of 0.07 and 0.7 mg/mL. After 3 days of single intra peritoneal (ip) injections of TCE in Sprague-Dawley rats at 0.05, 0.5, or 5 mmol/kg/day and B6C3F~1~ mice at 10 mmol/kg/day, natural killer cell activity in the liver, but not the spleen, was depressed in rats given the highest dose (22% lower than control levels, *p* \< 0.05); in mice, a smaller decrease was reported (14% lower than control levels), which was not statistically significant ([@b65-ehp-117-696]).

Data pertaining to measures of immunosuppression (e.g., infectious disease risk) in humans are very limited. In 1979, testing of wells in Woburn, Massachusetts, revealed that the water in two of the wells was contaminated with a number of solvents, including TCE (267 ppb) ([@b38-ehp-117-696]). In 1982, [@b38-ehp-117-696] used a telephone survey of Woburn residents (representing \~ 57% of the town residences with listed telephone numbers) to collect information on residential history and history of 14 types of medically diagnosed conditions for 4,978 children born since 1960 who lived in Woburn before they reached 19 years of age. Using exposure information based on estimates of the contribution of water from the contaminated wells in various zones within the town, [@b38-ehp-117-696] estimated a cumulative exposure based on each child's length of residence in Woburn. They found that a higher cumulative exposure measure was associated with a history of kidney and urinary tract disorders (primarily kidney or urinary tract infections) and with lung and respiratory disorders (asthma, chronic bronchitis, or pneumonia).

Studies of Generalized Hypersensitivity Skin Diseases with Other Systemic Effects
---------------------------------------------------------------------------------

Occupational exposure to TCE has been associated with a severe, generalized skin disorder that is distinct from contact dermatitis in its clinical presentation (which often involves mucosal lesions) and in the accompanying systemic effects, which can include lymphadenopathy, hepatitis, and other organ involvement. In two studies investigating delayed hypersensitivity using the guinea pig maximization test, sensitization rates of 66--71% and skin edema and erythema were observed ([@b60-ehp-117-696], [@b59-ehp-117-696]). Elevations in liver enzymes and presence of liver lesions were also reported by [@b59-ehp-117-696]. In the guinea pig maximization test they found histopathologic evidence of fatty degeneration in the liver, hepatic sinusoid dilation, and inflammatory cell infiltration with an acute intradermal dose of 4,500 mg/kg, and diffuse ballooning without lymphocytic infiltration or necrotic hepatocytes with a total dosage of ≤ 340 mg/kg.

[@b29-ehp-117-696] reviewed case reports describing 260 patients, mostly from Asia, with TCE-related generalized skin disorders. Their review is based on 26 articles published between 1966 and 2005 describing cases seen in China, Korea, Japan, Philippines, Singapore, Thailand, Spain, and the United States. One study in Guandong province, in southeastern China, included \> 100 cases in a single year ([@b27-ehp-117-696]). [@b29-ehp-117-696] categorized case descriptions as indicative of hypersensitivity syndrome (*n* = 124) or a variation of erythema multiforme, Stevens-Johnson syndrome, and toxic epiderma necrolysis (*n* = 115), with 21 other cases unclassified in either category. Hepatitis was common (\> 50%), and the fatality rate (\~ 10%) was similar in the two groups. Based on the reports reviewed by [@b29-ehp-117-696], generalized skin disease within a work-site occurred in 0.25--13% of workers in the same location performing the same type of work. The measured concentration of TCE ranged from \< 50 mg/m^3^ to \> 4,000 mg/m^3^, and exposure scenarios included inhalation only and inhalation with dermal exposures. Disease manifestation generally occurred within 2--5 weeks of initial exposure, with some intervals of up to 3 months. Most of the reports were published after 1995, and the geographic distribution of cases reflects the newly industrializing areas within Asia. An analysis of breathing zone concentrations of volatile organochlorines and metal contaminants of the solvents used in factories of 25 workers hospitalized for hyper sensitivity skin disease and at similar factories with no affected workers in the past 3 years indicated no commonality of additives or impurities detected among the affected factories that could explain the occurrence of the hypersensitivity disorder ([@b30-ehp-117-696]).

Autoimmune Disease Studies
--------------------------

### Autoimmune mouse models

#### Acceleration of autoimmune response

Several mouse strains spontaneously develop conditions resembling systemic lupus erythematosus seen in humans. These strains have been extensively used in mechanistic research pertaining to disease pathogenesis. The MRL-*lpr* and NZB × NZW mouse strains exhibit extremely high disease penetrance and early death. The MRL^+/+^ strain is less severely affected, with disease development after 12 months (compared with 6--8 months in MRL-*lpr* and female NZB × NZW mice) and a relatively low prevalence of renal involvement. The MRL^+/+^ mouse has been used most often in experimental studies of TCE exposure ([Table 1](#t1-ehp-117-696){ref-type="table"}).

Several studies in MRL^+/+^ mice reported autoimmune-related effects from exposure to TCE via drinking water ([@b6-ehp-117-696], [@b4-ehp-117-696]; [@b9-ehp-117-696]; [@b20-ehp-117-696]; [@b23-ehp-117-696], [@b24-ehp-117-696], [@b25-ehp-117-696]; [@b62-ehp-117-696]) or ip injection ([@b11-ehp-117-696]; [@b33-ehp-117-696]) ([Table 1](#t1-ehp-117-696){ref-type="table"}). The initial drinking water study used relatively high TCE concentrations of 2.5 and 5 mg/mL, with serologic measurements of ANA and IgG levels and assays of activation of CD4^+^ T cells from splenocytes ([@b20-ehp-117-696]; [@b23-ehp-117-696]). Another study examined lower exposure levels (0.1, 0.5, and 2.5 mg/mL) and extended the observation to 32 weeks ([@b24-ehp-117-696]). These studies demonstrated an acceleration of the autoimmune response. T-cell activation peaked at 4--8 weeks in the higher-dose experiment and at 32 weeks in the lower-dose experiment. The higher dose study showed evidence of a reversal in effects at 22 weeks, with lower levels of CD4^+^ T-cell expression and interferon-γ (IFN-γ) in exposed mice compared with controls. The effects observed by [@b23-ehp-117-696] with respect to formation of TCE--protein adducts and CD4^+^ T-cell activation were blocked in a parallel study of 2.5 mg/mL TCE via drinking water in which the CYP2E1 metabolic pathway was inhibited by the addition of dial-lyl sulfide ([@b25-ehp-117-696]). In another longer-exposure duration study using one dose group (0.5 mg/mL TCE in drinking water), [@b9-ehp-117-696] found no evidence of systemic inflammation as determined by serum cytokines measured after 36--48 weeks of exposure: levels of two proinflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), were decreased, but there was no difference in IL-1α.

Several studies demonstrated the involvement of one or more potential metabolites of TCE in the autoimmune response seen in MRL^+/+^ mice. These include studies of dichloroacetyl chloride ([@b33-ehp-117-696], [@b34-ehp-117-696]), trichloroacetaldehyde hydrate ([@b6-ehp-117-696], [@b4-ehp-117-696]), and trichloroacetic acid ([@b6-ehp-117-696]) ([Table 1](#t1-ehp-117-696){ref-type="table"}). Effects were similar to those found with TCE in terms of accelerated autoantibody expression, T-cell activation, and secretion of inflammatory cytokines, but some differences in clinical expression were found in the long-term studies. B-cell activation has not been observed in studies using TCE ([@b23-ehp-117-696]) or its metabolites ([@b6-ehp-117-696]).

#### Chronic effects

The three chronic oral exposure studies in the MRL^+/+^ mouse, with exposure periods of 32--48 weeks, reported the presence of distinct clinical effects in exposed mice ([Table 1](#t1-ehp-117-696){ref-type="table"}). One of these effects was characterized as an auto immune hepatitis ([@b9-ehp-117-696]; [@b24-ehp-117-696]). [@b24-ehp-117-696] found an inflammatory hepatic infiltrate in the portal tracts and lobular focal areas in the 0.5- and 2.5-mg/mL groups, with a dose-related effect on severity scores seen at 32 weeks. Alanine aminotransferase was also increased in the 0.5 mg/mL TCE dose group (means, 38.2 and 20.0 IU/L for 0.5 mg/mL and control groups, respectively). [@b9-ehp-117-696] found similar liver lymphocytic infiltrates at 36 weeks and 48 weeks in a study using 0.5 mg/mL TCE exposure in drinking water, and infiltrates in the pancreas, lungs, and kidneys at 48 weeks. In a 40-week study using trichloroacetaldehyde hydrate, [@b4-ehp-117-696] found clinical effects, including diffuse alopecia and skin inflammation and ulceration, with increasing incidence across the dose groups; the difference between the 0.9 mg/mL group and the controls was statistically significant. Histologic examination of the skin lesions showed mono nuclear cell infiltration, mast cell hyperplasia, and dermal fibrosis.

A chronic (26-week) drinking water exposure study in NZB × NZW mice reported an increased level of proteinuria and prevalence of renal pathology, but no evidence of liver disease, with a TCE exposure of 10,000 ppb in drinking water ([@b21-ehp-117-696]) ([Table 1](#t1-ehp-117-696){ref-type="table"}). Production of anti--double-stranded DNA (anti-dsDNA) and other antibodies was increased at 1,400 ppb TCE (but not 14,000 ppb) at 19 weeks; the differences lessened from 23 to 30 weeks and then increased between 32 and 34 weeks.

In a study in the male MRL-*lpr/lpr* mouse, [@b31-ehp-117-696] exposed the mice via inhalation for 8 weeks to 0, 500, 1,000, or 2,000 ppm TCE (4 hr/day, 6 days/week). IgG and IgM levels were reduced, but IgA levels and levels of T-helper and T-suppressor cells did not differ across exposures over the course of the study. The authors also found histologic changes in the liver and spleen, but not in the thymus, in the highest dose group ([Table 1](#t1-ehp-117-696){ref-type="table"}).

#### *In vitro* and mechanistic studies

Initial studies of TCE exposure in MRL^+/+^ mice noted the activation of a specific immune serum antibody response directed against dichloroacetylated proteins ([@b20-ehp-117-696]; [@b23-ehp-117-696]; [@b33-ehp-117-696]). Immunohistochemical staining also revealed TCE-modified protein adducts in the liver and lung ([@b20-ehp-117-696]; [@b23-ehp-117-696]). [@b10-ehp-117-696] extended these observations using an experiment involving immunization of various albumin adducts (trichloroethene oxide, dichloroacyl, formyl, and trifluroacyl) injected subcutaneously for 0, 2, or 4 weeks in groups of five female MRL^+/+^ mice. The authors used trifluroacyl albumin adduct as a positive control based on its role in halothane autoimmune liver disease. The immunogenicity of the protein adducts was demonstrated by the increased albumin-specific IgG seen in all albumin-adduct--treated groups. Cross-reactivity between adducts was also evident. Although [@b10-ehp-117-696] found no differences in serum liver enzymes (alanine aminotransferase and aspartate aminotransferase), the formyl-albumin immunization resulted in a hepatic lymphocyte infiltration. These results suggest that the production of formyl-haptenized proteins from TCE may be a key factor in the development of the effects seen in the MRL^+/+^ mouse studies.

A series of experiments examined the role for oxidative stress, and specifically of lipid-peroxidation-derived aldehydes, in TCE-induced autoimmune disease. The hypothesized mechanism involves the binding of these reactive aldehydes to proteins to form neoantigen targets for autoantibody formation. [@b61-ehp-117-696] detected malondialdehyde and 4-hydroxynonenal protein adducts (reflecting lipid peroxidation) in the livers of female MRL^+/+^ mice treated for 6 and 12 weeks with 10 mmol/kg TCE (every fourth day, by ip injection). The same group found antimalondialdehyde anti bodies and antihydroxynonenal antibodies with 4- to 12-week ip exposure to TCE ([@b34-ehp-117-696]; [@b61-ehp-117-696], [@b62-ehp-117-696], [@b63-ehp-117-696]) and 48-week oral exposure to TCE ([@b62-ehp-117-696]) or dichloroacetyl chloride ([@b34-ehp-117-696]). These antibodies were correlated with ANA ([@b61-ehp-117-696], [@b62-ehp-117-696]). [@b63-ehp-117-696] found proliferation and activation of splenic CD4^+^ T cells after stimulation with malondialdehyde-adducted or 4-hydroxy-nonenal--adducted mouse serum albumin.

Other studies have examined potential mechanisms through which TCE-related compounds affect T-cell stimulation and apoptosis. In a short-term (4-week) exposure study, [@b6-ehp-117-696] found a dose-related inhibition of anti-CD3--mediated (activation-induced) apoptosis of CD4^+^ T cells with oral exposures to 0, 0.1, and 0.9 mg/mL trichloroacetaldehyde hydrate. With a longer exposure period (40 weeks), however, they found no effect on anti-CD3--mediated apoptosis of CD4^+^ T cells and no difference in expression of Fas or Fas ligand ([@b4-ehp-117-696]). This difference paralleled a difference in metalloproteinase-7 levels, which were elevated at 4 weeks but not at 40 weeks ([@b4-ehp-117-696]; [@b5-ehp-117-696]).

### Other rodent models

The Brown Norway rat has been used as a model of chemical-induced complex-mediated glomerulonephritis, for example, in studies of mercuric chloride ([@b57-ehp-117-696]). The disease is complex-mediated, similar to that seen in humans with systemic lupus erythematosus. Polyclonal stimulation and increased IgE levels are hallmarks of the disease in the Brown Norway rat. [@b64-ehp-117-696] administered TCE by gavage to female Brown Norway rats for 6 weeks (100, 200, or 400 mg/kg, 6--8 animals per dose) and found no increase in IgE compared with the vehicle controls.

In the study of NZB × NZW mice described above, [@b21-ehp-117-696] also included a parallel study of B6C3F~1~ mice, a model that typically does not develop auto-immune sequelae. Increases in anti-dsDNA antibodies were statistically significant or of borderline significance (*p* = 0.07) at all times after 26 weeks exposure to 1,400 ppb or 14,000 ppb TCE via drinking water.

Epidemiologic Studies
---------------------

### Measures of immune function and markers

The available data from studies in humans also provide evidence of an association between increased TCE exposure and cytokine measures indicative of an inflammatory immune response ([Table 2](#t2-ehp-117-696){ref-type="table"}). [@b28-ehp-117-696] examined cytokine levels in 35 male TCE-exposed workers (degreasers) from a printing area of a factory in Italy and compared these workers with two control groups: other male factory workers not involved in degreasing activities (*n* = 30) and male office workers at the factory (*n* = 40). The mean TCE concentration among exposed workers was approximately 35 mg/m^3^. The authors observed no difference in serum cytokine concentrations (measured using enzyme-linked immunosorbent assays) between the two control groups, but they found considerable differences in the exposed group compared with the nonexposed workers (for all, *p* \< 0.01): exposed workers had lower IL-4 levels and higher IL-2 and IFN-γ levels ([Table 2](#t2-ehp-117-696){ref-type="table"}).

Two other studies measured the percentage of cytokine-secreting CD3^+^ (or CD3^+^ and CD8^+^) T cells in relation to measures of TCE exposure from indoor air samples. [@b42-ehp-117-696] found no association in the pilot study conducted with 28 children 36 months of age, but a larger study of 85 infants (4 weeks of age) reported a decrease in the population of IL-4--secreting cells and an increase in IFN-γ--secreting cells in relation to higher exposure to TCE (defined as \> 75th percentile of the distribution) ([@b43-ehp-117-696]).

[@b8-ehp-117-696] collected serum samples from 23 family members of leukemia patients in Woburn. They used these samples to assess the presence of autoantibodies (ANA, anti-smooth muscle, anti ovarian, anti thyroglobulin, and antimicrosomal antibodies) in the family member samples and compared the results with laboratory reference values. None of the serum samples from family member contained antithyroglobulin or antimicrosomal antibodies, but ANA were detected in samples from 10 (43%) family members (compared with \< 5% expected based on the reference value).

The aquifer of the Santa Cruz River in Tucson, Arizona, had been contaminated with solvents (primarily TCE) and heavy metals (e.g., chromium). [@b35-ehp-117-696], [@b36-ehp-117-696] examined the prevalence of connective tissue disease symptoms and ANA, comparing 362 residents of Tucson to 158 residents of another area of southwest Arizona. They selected the Tucson residents from the neighborhoods with documented water contamination (\> 5 ppb TCE for at least 1 year between 1957 and 1981). The recruitment process was not described clearly, but in Tucson it seems to have specifically involved patients with lupus or other rheumatic diseases ([@b35-ehp-117-696], [@b36-ehp-117-696]). In contrast, they recruited the comparison group through a Catholic parish. The prevalence of some self-reported symptoms (malar rash, arthritis/arthalgias, Raynaud syndrome, skin lesions, and seizure or convulsion) and of low-titer (1:80) ANA was higher in Tucson ([@b35-ehp-117-696]). It is difficult to attribute these differences to the water supply, however, given the process that went into participant recruitment (with part of the Tucson group selected based on the presence of rheumatic diseases) and the lack of verification of the self-reported symptoms.

### Systemic autoimmune diseases

Interest in the role of chlorinated compounds in auto-immune diseases was spurred by the observation of a scleroderma-like disease in workers exposed to vinyl chloride ([@b18-ehp-117-696]), and several case reports focused on TCE ([@b17-ehp-117-696]; [@b44-ehp-117-696]; [@b55-ehp-117-696]). Larger epidemiologic studies (case--control or population-registry--based designs) using broad measures of occupational exposure to solvents, organic solvents, or chlorinated solvents generally reported a 2- to 3-fold increased risk of systemic sclerosis (scleroderma) ([@b2-ehp-117-696]; [@b19-ehp-117-696]; [@b46-ehp-117-696]), rheumatoid arthritis ([@b45-ehp-117-696]; [@b58-ehp-117-696]), undifferentiated connective tissue disease ([@b37-ehp-117-696]), and anti-neutrophil-cytoplasmic antibody (ANCA)--related vasculitis ([@b3-ehp-117-696]; [@b39-ehp-117-696]), but similar associations have not been found in studies of lupus ([@b12-ehp-117-696]; [@b16-ehp-117-696]).

Two case--control studies of scleroderma ([@b7-ehp-117-696]; [@b46-ehp-117-696]) and two of rheumatoid arthritis ([@b52-ehp-117-696], [@b51-ehp-117-696]) provided data concerning solvent exposure that occurred among metal workers or in jobs that involved cleaning metal (i.e., types of jobs that were likely to use TCE as a solvent). [@b52-ehp-117-696], [@b51-ehp-117-696] found a 2-fold increased risk among male workers in studies of rheumatoid arthritis from Sweden. The results from the smaller studies of scleroderma were more variable: [@b46-ehp-117-696] found no exposed cases in a study with 93 cases and 206 controls, and [@b7-ehp-117-696] found an odds ratio (OR) of 5.2 \[95% confidence interval (CI), 0.7--37\] in a study with 56 cases and 171 controls.

Five other case--control studies provided data specifically about TCE exposure, based on industrial hygienist review of job history data ([Table 3](#t3-ehp-117-696){ref-type="table"}). Three of these studies are of scleroderma ([@b15-ehp-117-696]; [@b19-ehp-117-696]; [@b50-ehp-117-696]), one is of undifferentiated connective tissue disease ([@b37-ehp-117-696]), and one is of small vessel vasculitis involving ANCA ([@b3-ehp-117-696]). These studies included some kind of expert review of job histories, but only two studies included a characterization of exposure level (e.g., a cumulative exposure metric) or a "high" exposure group ([@b15-ehp-117-696]; [@b50-ehp-117-696]). Most of the studies presented data stratified by sex. The test for heterogeneity between results for males and those for females just missed statistical significance (*p* = 0.058). We decided that performing separate analyses for these groups was warranted because the substantial gender-related differences in the background rate of scleroderma and in the prevalence of TCE exposure provide additional rationale for examining gender-related differences in measures of association. In men, the studies generally reported ORs between 2.0 and 8.0, and in women, the ORs were between 1.0 and 2.0. The meta-analysis of scleroderma studies with TCE exposure data ([@b15-ehp-117-696]; [@b19-ehp-117-696]; [@b50-ehp-117-696]) resulted in a combined OR for "any" exposure of 2.5 (95% CI, 1.1--5.4) for men and 1.2 (95% CI, 0.58--2.6) for women ([Figure 1](#f1-ehp-117-696){ref-type="fig"}). There was no clear support for heterogeneity within the male and female subgroupings (*p* = 0.35 for men and 0.16 for women).

Discussion
==========

During the past decade there has been considerable research, in experimental animals and in humans, pertaining to immune-related effects of TCE. Data concerning immunosuppression, particularly in humans, are still somewhat limited. In contrast, a fuller picture is shown by the studies of hypersensitivity, dermatitis, and hepatic injury, an emerging occupational concern in China and other industrializing areas.

The autoimmune-related studies, many of which were conducted in the past 5 years, represent a broad and robust literature, exhibiting many of the attributes that lend support for a causal relation between exposure and disease, including strength, consistency, dose--response patterns, and biological plausibility ([@b26-ehp-117-696]; [@b41-ehp-117-696]). Autoimmune mouse strains with a relatively less severe lupus phenotype (i.e., delayed disease onset), such as seen in the MRL^+/+^ mouse, provide an experimental model to examine the acceleration of lupus pathology. Numerous studies using different routes of exposure and dose ranges have demonstrated an accelerated autoimmune response in MRL^+/+^ mice. In the oral exposure studies, the duration of exposure period clearly influences the observed effects, with the acceleration (as measured by auto-antibody production, T-cell activation, and inflammatory cytokine secretion or serum levels) generally seen with shorter exposures ([@b6-ehp-117-696]; [@b23-ehp-117-696], [@b24-ehp-117-696]), and clinical effects seen with longer exposure periods ([@b4-ehp-117-696]; [@b9-ehp-117-696]; [@b21-ehp-117-696]; [@b24-ehp-117-696]). The different effects seen with short compared with long exposure durations in the MRL^+/+^ mouse experiments may reflect the varying disease course and varying response in specific target tissues during different phases of pathogenesis ([@b22-ehp-117-696]). It is interesting that the clinical effects seen in the MRL^+/+^ mouse chronic exposure studies (36--48 weeks) ([@b4-ehp-117-696]; [@b9-ehp-117-696]; [@b24-ehp-117-696]) differ somewhat from "normal" expression within these mice. That is, the effects seen included an inflammatory hepatic infiltrate, diffuse alopecia, and skin inflammation and ulceration.

Studies using autoimmune mouse strains also provide a means to examine potential mechanisms of action as well as the effects of various doses and durations of exposure. The formation of immunogenic TCE-induced adducts of liver proteins and lipid-peroxidation--derived aldehydes and potential role of oxidative stress in promoting an aberrant autoimmune response to neoantigens in the liver and other tissues are some of the mechanistic hypotheses that have been raised by this research.

Data from experimental studies in non-lupus-prone animals are limited. In a study in the Brown Norway rat, [@b64-ehp-117-696] found no increase in IgE with gavage doses of up to 400 mg/kg-day for 6 weeks, but [@b21-ehp-117-696] found increases in anti-dsDNA antibodies in B6C3F~1~ mice after 26 weeks of exposure to 1,400 ppb or 14,000 ppb via drinking water.

Are the effects seen in the MRL^+/+^ mouse also seen in humans? Occupational studies have examined inflammatory cytokines and specific systemic autoimmune diseases, although our literature search did not find any studies of TCE exposure and either lupus or autoimmune liver disease. We found no cohort studies of the incidence of auto immune diseases in workers exposed to TCE, but the available case--control studies of scleroderma and TCE support the relevance of this disease within the context of human exposures. Although the association is generally stronger in studies in men compared with those in women, it is not clear whether this difference reflects the relatively low background risk of scleroderma in men, differences in exposure prevalence or in the reliability of exposure assessment ([@b47-ehp-117-696]), or a gender-related difference in susceptibility to the effects of TCE. Given the available studies in scleroderma and more limited data in other systemic autoimmune diseases, it is difficult to argue that the investigations into disease acceleration and variations in manifestations of effect seen in lupus-prone mice are irrelevant to humans. The variation in clinical expression of disease in response to TCE exposure remains an important research question to be addressed by both mechanistic and epidemiologic studies.

Systemic sclerosis (scleroderma) and autoimmune liver disease are relatively rare in humans, with incidence rates of about 1/100,000 per year; incidence rates for systemic lupus erythematosus are somewhat higher (5--10 per 100,000 per year) ([@b13-ehp-117-696]) but still low enough to present considerable challenges to performing adequately powered epidemiologic studies. An additional impediment to autoimmune disease research is the lack of disease registries, which adds to the difficulty in identifying incident cases of specific diseases. The insights generated by the recent experimental studies of TCE, however, provide a strong rationale for developing the type of multi site collaborations needed to address the potential influence of TCE or other solvents operating through a similar pathway on the incidence of specific autoimmune diseases, and for evaluating the potential immune-related effects of low-level exposures from environmental contamination. Development and validation of exposure assessment techniques incorporating occupational and environmental exposure pathways, use of quantitative exposure metrics, examination of multiple solvents and other agents, and studies of markers of immune function expressed before onset of disease would be instrumental in the further advancement of these efforts.

The views expressed are those of the authors and do not necessarily reflect the views or policies of the U.S. Environmental Protection Agency.

![Association between risk of scleroderma and occupational exposure to TCE in men (*A*) and women (*B*), based on data from three case--control studies ([@b15-ehp-117-696]; [@b19-ehp-117-696]; [@b50-ehp-117-696]). The graphics show the estimated measures of association from these studies. The pooled estimates are based on a meta-analysis using a random-effects model to include the possibility of nonrandom error between studies. Each square and corresponding line represent the OR and 95% CI from the individual study, with the relative size of the squares reflecting the relative weights of the studies. The horizontal midpoint of each diamond represents the pooled OR estimate and the horizontal extremes indicate the 95% CI.](ehp-117-696f1){#f1-ehp-117-696}

###### 

Studies of TCE and metabolite effects[a](#tfn2-ehp-117-696){ref-type="table-fn"} in lupus mouse strains by strain, exposure route, and duration.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Strain, reference(s), exposure                                                                                                                   Serology                                                                                                                                                                        Studies of cultured splenocytes                                                                                                                                                                                                                                                      Clinical/histopathology results
  ------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Female MRL^+/+^ mice, drinking water                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@b20-ehp-117-696]; [@b23-ehp-117-696]\                                                                                                          Increased ANA at 4 and 8 weeks; no difference between groups at 22 weeks                                                                                                        Increased activated CD4^+^ T cells and IFN-γ secretion across doses at 4 weeks, with effects reversed at 22 weeks; decreased IL-4 secretion (4 and 22 weeks)                                                                                                                         No evidence of liver or renal damage, based on serum alanine aminotransferase, sorbitol dehydrogenase, and blood urea nitrogen
   No. per group; 0, 2.5, 5 mg/mL TCE (average 0, 455, 734 mg/kg-day) for 4, 8, or 22 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  [@b25-ehp-117-696]\                                                                                                                              Increased ANA in all treated groups at 4 weeks but not at 32 weeks                                                                                                              Increased activated CD4^+^ T cells (32 weeks) and IFN-γ secretion (4 and 32 weeks); no effect on IL-4 secretion                                                                                                                                                                      Extensive hepatic mononuclear cellular infiltrate in 0.5 and 2.5 mg/mL groups; hepatocyte reactive changes in all treated groups at 32 weeks
   8 per group; 0, 0.1, 0.5, or 2.5 mg/mL TCE (0, 21, 100, or 400 mg/kg-day) for4 or 32 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  [@b6-ehp-117-696]\                                                                                                                               Increased ANA and anti-histone antibodies at 0.9 mg/mL trichloroacetaldehyde hydrate[b](#tfn3-ehp-117-696){ref-type="table-fn"}                                                 Increased activated CD4^+^ T cells at 0.1 and 0.9 g/mL doses of both metabolites; increased IFN-γ secretion at 0.9 mg/mL; no effect on IL-4 secretion                                                                                                                                No evidence of liver or kidney damage, based on serum alanine aminotransferase and liver and kidney histology
   6--8 per group; 0, 0.1, 0.9 mg/mL trichloroacetaldehyde hydrate (0, 24, 220 mg/kg) or trichloroacetic acid (0, 27, 205 mg/kg-day) for 4 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@b4-ehp-117-696]\                                                                                                                               Slightly suppressed anti-ssDNA, anti-dsDNA, and anti-histone antibody expression; differences not statistically significant                                                     Increased activated CD4^+^ T-cells and increased IFN-γ secretion; no effect on IL-4 secretion                                                                                                                                                                                        Diffuse alopecia, skin inflammation and ulceration, mononuclear cell infiltration, mast cell hyperplasia, and dermal fibrosis; statistically significant increase at 0.9 mg/mL dose group but also increased at lower doses; no liver or kidney histopathology effects seen
   8 per group, 0, 0.1, 0.3, 0.9 mg/mL trichloroacetaldehyde hydrate (0, 13, 46, 143 mg/kg-day) for 40 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  [@b9-ehp-117-696]\                                                                                                                               Increased ANA after 24 weeks but not statistically significant                                                                                                                  Increased IFN-γ secretion after 36 weeks but not statistically significant                                                                                                                                                                                                           Hepatic necrosis; hepatocyte proliferation; leukocyte infiltrate in the liver, lungs, and kidneys; no difference in serum aminotransferase liver enzymes
   5 per group, 0 or 0.5 mg/mL TCE (mean 60 μg/g-day) for 48 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Female MRL^+/+^ mice, ip injection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@b33-ehp-117-696]\                                                                                                                              In both groups, increased ANA and anti-ssDNA antibodies; in dichloroacetyl chloride group, anticardiolipin antibodies; no difference in anti-histone, -Sm, or -DNA antibodies   Not evaluated                                                                                                                                                                                                                                                                        Not evaluated
   4--5 per group, in corn oil, 0 (corn oil), 10 mmol/kg TCE, 0.2 mmol/kg dichloroacetyl chloride, every 4th day for 6 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  [@b11-ehp-117-696]\                                                                                                                              In both treated groups, increased ANA                                                                                                                                           In both treated groups, increased IL-1α, IL-1β, IL-3, IL-6, IFN-γ, granulocyte colony--stimulating factor, and keratinocyte-derived chemokine secretion and decreased IL-5; in dichloroacetyl chloride group, increased IL-17 and IFN-α[c](#tfn4-ehp-117-696){ref-type="table-fn"}   In both treated groups, increased lymphocytes in spleen and thickening of alveolar septa with lymphocytic interstitial infiltration
   6 per group, in corn oil, 0 (corn oil), 0.2 mmol/kg dichloroacetyl chloride, 0.2 mmol/kg dichloroacetic anhydride, twice per week for 6 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Female NZB × NZW mice, drinking water                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@b21-ehp-117-696]\                                                                                                                              Increased anti-dsDNA antibodies at some periods at ≥ 1,000 ppb                                                                                                                  Not evaluated                                                                                                                                                                                                                                                                        At 10,000 ppb, proteinuria increased beginning at 20 weeks; renal pathology scores increased; no signs of liver disease
   6 per group, 0, 1,400, or 14,000 ppb,[d](#tfn5-ehp-117-696){ref-type="table-fn"} 26 weeks exposure; observed up to 36 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Male MRL --*lpr/lpr*, inhalation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@b31-ehp-117-696]\                                                                                                                              Not evaluated                                                                                                                                                                   Not evaluated                                                                                                                                                                                                                                                                        At ≥ 500 ppm, dose-related liver inflammation, splenomegaly, and hyperplasia of lymphatic follicles; at 1,000 ppm, immunoblastic cell formation in lymphatic follicles; no changes in thymus
   5 per group, 0, 500, 1,000, 2,000 ppm TCE, 4 hr/day, 6 days/week for 8 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ssDNA, single-strand DNA.

Selected end points based on those reported across most studies.

No difference reported in anti-dsDNA, anti-ss-DNA, anti-ribonucleosome, anti-SSA, anti-SSB, anti-Sm, anti-Jo-1, or anti-Scl-70 antibodies.

No difference in secretion of other cytokines measured: IL-2, IL-4, IL-10, IL-12, TNF-α, granulocyte monocyte colony--stimulating factor, macrophage inflammatory protein-1α, and RANTES (CCL-5).

Dose not given in mg/kg-day. Dose levels cited by [@b21-ehp-117-696] were incorrectly reported as 1,000 and 10,000 ppb; corrected doses (Peden-Adams MM, personal communication) are reported here.

###### 

Studies of cytokines and TCE exposure in humans.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference, location, no., and age                                                                                  Source of exposure data, outcome measures                                                                                                                                                                      Results
  ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@b28-ehp-117-696]\                                                                                                Urine sample (for trichloroacetic acid concentration); workplace TCE measures (personal samples, 4 exposed and 4 nonexposed workers); questionnaire (smoking history, age, residence); serum cytokine levels   Nonexposed workers similar to office controls for all cytokine measures; compared with nonexposed workers, TCE-exposed workers had decreased IL-4 (mean, 3.9 vs. 8.1 pg/mL), increased IL-2 (mean, 798 vs. 706 pg/mL), and increased IFN-γ (mean, 37.1 vs. 22.9 pg/mL)
   Italy; 35 exposed workers, 30 nonexposed workers, and 40 office worker controls, all male; mean age \~ 33 years                                                                                                                                                                                                                  

  [@b42-ehp-117-696]\                                                                                                Indoor air sampling (child's bedroom) of 28 volatile organic chemicals; cytokine-secreting CD3^+^ and CD8^+^ T cell populations from blood sample                                                              TCE exposure not associated with percentages of IL-4 CD3^+^ or IFN-γ CD8^+^ T-cells
   Germany; 28 children, 36 months of age                                                                                                                                                                                                                                                                                           

  [@b43-ehp-117-696]\                                                                                                Indoor air sampling (child's bedroom) of 28 volatile organic chemicals (4 weeks after birth); cytokine-secreting CD3^+^ T cell populations from CD3^+^ cord blood cells                                        Increasing TCE levels associated with decreased IL-4 (OR = 4.4; 95% CI, 1.1--17.8) for \< 25th percentile IL-4 and increased IFN-γ (OR = 3.6; 95% CI, 0.9--14.9) for \> 75th percentile IFN-γ; no association with TNF-α or IL-2
   Germany; 85 newborns                                                                                                                                                                                                                                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Epidemiologic studies of TCE exposure and risk of scleroderma and other autoimmune diseases.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease, reference, location, period, sample size, age                                                                                                                    Source of exposure data                                                                                                     Exposure definition/prevalence                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------- ------ ------ -------------------
  Scleroderma (systemic sclerosis)                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                  

  [@b50-ehp-117-696]\                                                                                                                                                       Structured interview (specific jobs and materials; jobs held ≥ 1 year); classified by expert review (job exposure matrix)   Men                                                                       
   South Carolina; prevalent cases, 1995--1997; 178 cases (141 women, 37 men), 200 hospital-based controls; mean age at onset, 45.2 years                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                         Any exposure[a](#tfn7-ehp-117-696){ref-type="table-fn"}    51     42     2.0 (0.8--4.9)

                                                                                                                                                                                                                                                                                                         Maximum intensity                                          30     10     3.3 (1.0--10.3)

                                                                                                                                                                                                                                                                                                         Cumulative intensity                                       32     21     2.0 (0.7--5.3)

                                                                                                                                                                                                                                                                                                         Maximum probability                                        16     3      5.1 (NC)

                                                                                                                                                                                                                                                                                                        Women                                                                     

                                                                                                                                                                                                                                                                                                         Any exposure[a](#tfn7-ehp-117-696){ref-type="table-fn"}    19     24     0.7 (0.4--1.3)

                                                                                                                                                                                                                                                                                                         Maximum intensity                                          6      7      0.9 (0.3--2.3)

                                                                                                                                                                                                                                                                                                         Cumulative intensity                                       10     9      1.2 (0.5--2.6)

                                                                                                                                                                                                                                                                                                         Maximum probability                                        4      5      0.7 (0.2--2.2)

  [@b15-ehp-117-696]\                                                                                                                                                       Structured interview (specific jobs and materials; jobs held ≥ 6 months); classified by expert review                       Men and women                                                             
   France; prevalent cases hospitalized 1998--2000; 80 cases (69 women, 11 men), 160 hospital controls; mean age at diagnosis, 48 years                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                         Any exposure                                               16     8      2.4 (1.0--5.2)

                                                                                                                                                                                                                                                                                                         High exposure[b](#tfn8-ehp-117-696){ref-type="table-fn"}   9      1      7.6 (1.5--37.4)

                                                                                                                                                                                                                                                                                                        Men                                                                       

                                                                                                                                                                                                                                                                                                         Any exposure                                               64     27     4.7 (0.99--21.9)

                                                                                                                                                                                                                                                                                                        Women                                                                     

                                                                                                                                                                                                                                                                                                         Any exposure                                               9      4      2.1 (0.65--6.8)

  [@b19-ehp-117-696]\                                                                                                                                                       Structured interview (specific jobs and materials; jobs held ≥ 3 months); classified by self-report and expert review       Women                                                                     
   Michigan and Ohio; prevalent cases diagnosed 1980--1992; 660 cases (all women), 2,227 population controls;[c](#tfn9-ehp-117-696){ref-type="table-fn"} ages, ≥ 18 years                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                         Self-report, any exposure                                  1.3    0.7    2.0 (0.8--4.8)

                                                                                                                                                                                                                                                                                                         Expert review, any exposure                                0.7    0.4    1.9 (0.6--6.6)

                                                                                                                                                                                                                                                                                                                                                                                  

  Undifferentiated connective tissue disease                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                  

  [@b37-ehp-117-696]\                                                                                                                                                       Structured interview (specific jobs and materials; jobs held ≥ 3 months); classified by self-report and by expert review    Women                                                                     
   Michigan and Ohio; prevalent cases diagnosed 1980--1991 (Michigan), 1980--1992 (Ohio); 205 cases (all women), 2,095 population controls; ages, ≥ 18 years                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                         Self-report, any exposure                                  0.5    0.7    0.88 (0.11--6.95)

                                                                                                                                                                                                                                                                                                         Expert review, any exposure                                0.5    0.4    1.67 (0.19--14.9)

                                                                                                                                                                                                                                                                                                                                                                                  

  ANCA-related diseases[d](#tfn10-ehp-117-696){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                  

  [@b3-ehp-117-696]\                                                                                                                                                        Structured interview (specific jobs and materials; jobs held ≥ 6 months); classified by expert review                       Men and women                                                             
   France; incident cases diagnosed 1999--2000; 60 cases (\~ 50% women), 120 hospital controls; mean age, 61 years                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                         Any exposure                                               18.3   17.5   1.1 (0.5 -- 2.4)

                                                                                                                                                                                                                                                                                                         Data not presented separately by sex                                     
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NC, not calculated.

The publication did not include "any" exposure, but this was generated by the original author (P. Nietert) as part of the present analysis.

Product of probability × intensity × frequency × duration scores, summed across all jobs; scores of \> 1 classified as "high."

Total number with TCE data: self-report 606 cases, 2,138 control; expert review 606 cases, 2,137 controls.

Diseases included Wegener glomerulonephritis (*n* = 20), microscopic polyangiitis (*n* = 8), pauci-immune glomerulonephritis (*n* = 10), uveitis (*n* = 6), Churg-Strauss syndrome (*n* = 4), stroke (*n* = 4), and other diseases (≤ 2 each).

[^1]: The authors declare they have no competing financial interests.
